Adenosine-mediated effects of ticagrelor: Evidence and potential clinical relevance

Journal of the American College of Cardiology

Volumn 63, Issue 23, 2014, Pages 2503-2509

  Cattaneo, Marco ^a   Schulz, Rainer ^b   Nylander, Sven ^c  

^a UNIVERSITY OF MILAN   (Italy)

^b JUSTUS LIEBIG UNIVERSITY   (Germany)

^c ASTRAZENECA R AND D   (Sweden)

Author keywords

acute coronary syndrome(s); adenosine; antiplatelet agents; ticagrelor

Indexed keywords

ADENOSINE; CANGRELOR; CLOPIDOGREL; CYCLIC AMP; DIPYRIDAMOLE; ELINOGREL; EQUILIBRATIVE NUCLEOSIDE TRANSPORTER; G PROTEIN COUPLED RECEPTOR; NUCLEOSIDE TRANSPORTER; PRASUGREL; PURINERGIC P2Y12 RECEPTOR; TICAGRELOR; PURINERGIC P2Y RECEPTOR ANTAGONIST; ANTITHROMBOCYTIC AGENT; EQUILIBRATIVE NUCLEOSIDE TRANSPORTER 1;

ACUTE CORONARY SYNDROME; ARTICLE; CEREBROVASCULAR ACCIDENT; DRUG EFFICACY; DRUG MECHANISM; DRUG STRUCTURE; DYSPNEA; GLOMERULUS FILTRATION RATE; HEART FUNCTION; HEART INFARCTION; HEART INFARCTION SIZE; HUMAN; INCIDENCE; KIDNEY TUBULE ABSORPTION; NON ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; SINUS NODE; SUPRAVENTRICULAR TACHYCARDIA; THROMBOCYTE AGGREGATION; TISSUE INJURY; ANALOGS AND DERIVATIVES; METABOLISM; TREATMENT OUTCOME; BLOOD LEVEL; CELL METABOLISM; CELL TRANSPORT; CHRONOTROPISM; CLINICAL PRACTICE; CORONARY ARTERY DILATATION; DRUG ANTAGONISM; DRUG EFFECT; DRUG POTENTIATION; DRUG SAFETY; EVIDENCE BASED MEDICINE; INFLAMMATION; NONHUMAN; REPERFUSION INJURY; THROMBOCYTE AGGREGATION INHIBITION;

ACUTE CORONARY SYNDROME; ADENOSINE; HUMANS; PURINERGIC P2Y RECEPTOR ANTAGONISTS; TREATMENT OUTCOME;

EID: 84902214445     PISSN: 07351097     EISSN: 15583597     Source Type: Journal    
DOI: 10.1016/j.jacc.2014.03.031     Document Type: Review

References (60)

1. M. Cattaneo The platelet P2Y12 receptor for adenosine diphosphate: congenital and drug-induced defects Blood 117 2011 2102 2112
2. D.J. Angiolillo, N. Curzen, and P. Gurbel et al. Pharmacodynamic evaluation of switching from ticagrelor to prasugrel in subjects with stable coronary artery disease: results of the SWAP-2 Study J Am Coll Cardiol 63 2014 1500 1509
3. L. Wallentin, R.C. Becker, A. Budaj for the PLATO Investigators Ticagrelor versus clopidogrel in patients with acute coronary syndromes N Engl J Med 361 2009 1045 1057
4. S.D. Wiviott, E. Braunwald, C.H. McCabe for the TRITON-TIMI 38 Investigators Prasugrel versus clopidogrel in patients with acute coronary syndromes N Engl J Med 357 2007 2001 2015
5. J.J. DiNicolantonio, and A. Tomek Misrepresentation of vital status follow-up: challenging the integrity of the PLATO trial and the claimed mortality benefit of ticagrelor versus clopidogrel Int J Cardiol 169 2013 145 146
6. L. Wallentin, R.C. Becker, and C.P. Cannon et al. Review of the accumulated PLATO documentation supports reliable and consistent superiority of ticagrelor over clopidogrel in patients with acute coronary syndrome: Commentary on: DiNicolantonio JJ, Tomek A, Inactivations, deletions, non-adjudications, and downgrades of clinical endpoints on ticagrelor: serious concerns over the reliability of the PLATO trial, International Journal of Cardiology, 2013 Int J Cardiol 170 2014 e59 e62
7. S. De Servi, and S. Savonitto How to explain the reduced cardiovascular mortality in the ticagrelor arm of the PLATO trial? Int J Cardiol 149 2011 265 267
8. M. Cattaneo, and E.M. Faioni Why does ticagrelor induce dyspnea? Thromb Haemost 108 2012 1031 1036
9. D.J. Schneider Mechanisms potentially contributing to the reduction in mortality associated with ticagrelor therapy J Am Coll Cardiol 57 2011 685 687
10. J.P. Headrick, and R.D. Lasley Adenosine receptors and reperfusion injury of the heart Handb Exp Pharmacol 193 2009 189 214
11. A. Armstrong, C. Summers, L. Ewart, S. Nylander, J.E. Sidaway, and J.J. van Giezen Characterization of the adenosine pharmacology of ticagrelor reveals therapeutically relevant inhibition of equilibrative nucleoside transporter 1 J Cardiovasc Pharmacol Ther 19 2014 209 219
12. J.P. Headrick, K.J. Ashton, R.B. Rose'meyer, and J.N. Peart Cardiovascular adenosine receptors: expression, actions and interactions Pharmacol Ther 140 2013 92 111
13. G.H. Moser, J. Schrader, and A. Deussen Turnover of adenosine in plasma of human and dog blood Am J Physiol 256 1989 C799 C806
14. J.J. Van Giezen, J. Sidaway, P. Glaves, I. Kirk, and J.A. Björkman Ticagrelor inhibits adenosine uptake in vitro and enhances adenosine-mediated hyperemia responses in a canine model J Cardiovasc Pharmacol Ther 17 2012 164 172
15. S. Nylander, E.A. Femia, and M. Scavone et al. Ticagrelor inhibits human platelet aggregation via adenosine in addition to P2Y12 antagonism J Thromb Haemost 11 2013 1867 1876
16. A. Gamboa, R. Abraham, and A. Diedrich et al. Role of adenosine and nitric oxide on the mechanisms of action of dipyridamole Stroke 36 2005 2170 2175
17. B. Springthorpe, A. Bailey, and P. Barton et al. From ATP to AZD6140: the discovery of an orally active reversible P2Y12 receptor antagonist for the prevention of thrombosis Bioorg Med Chem Lett 17 2007 6013 6018
18. L. Bonello, M. Laine, and N. Kipson et al. Ticagrelor increases adenosine plasma concentration in patients with an acute coronary syndrome J Am Coll Cardiol 63 2014 872 877
19. R. Teng, S. Oliver, M.A. Hayes, and K. Butler Absorption, distribution, metabolism, and excretion of ticagrelor in healthy subjects Drug Metab Dispos 38 2010 1514 1521
20. G. Haskó, and B. Cronstein Regulation of inflammation by adenosine Front Immunol 4 2013 85
21. S.J. Mustafa, R.R. Morrison, B. Teng, and A. Pelleg Adenosine receptors and the heart: role in regulation of coronary blood flow and cardiac electrophysiology Handb Exp Pharmacol 193 2009 161 188
22. M.A. Talukder, R.R. Morrison, M.A. Jacobson, K.A. Jacobson, C. Ledent, and S.J. Mustafa Targeted deletion of adenosine A(3) receptors augments adenosine-induced coronary flow in isolated mouse heart Am J Physiol Heart Circ Physiol 282 2002 H2183 H2189
23. M.A. Talukder, R.R. Morrison, C. Ledent, and S.J. Mustafa Endogenous adenosine increases coronary flow by activation of both A2A and A2B receptors in mice J Cardiovasc Pharmacol 41 2003 562 570
24. H.E. Tawfik, B. Teng, R.R. Morrison, J. Schnermann, and S.J. Mustafa Role of A1 adenosine receptor in the regulation of coronary flow Am J Physiol Heart Circ Physiol 291 2006 H467 H472
25. 3 receptors are involved in the human endothelial progenitor cells migration J Cardiovasc Pharmacol 59 2012 397 404
26. D.D. Dawicki, K.C. Agarwal, and R.E. Parks Jr. Role of adenosine uptake and metabolism by blood cells in the antiplatelet actions of dipyridamole, dilazep and nitrobenzylthioinosine Biochem Pharmacol 34 1985 3965 3972
27. H.A. Johnston-Cox, D. Yang, and K. Ravid Physiological implications of adenosine receptor-mediated platelet aggregation J Cell Physiol 226 2011 46 51
28. D. Yang, H. Chen, and M. Koupenova et al. A new role for the A2b adenosine receptor in regulating platelet function J Thromb Haemost 8 2010 817 827
29. K.E. Barletta, K. Ley, and B. Mehrad Regulation of neutrophil function by adenosine Arterioscler Thromb Vasc Biol 32 2012 856 864
30. B. Csóka, Z.H. Németh, and P. Rosenberger et al. A2B adenosine receptors protect against sepsis-induced mortality by dampening excessive inflammation J Immunol 185 2010 542 550
31. B.P. Ramakers, N.P. Riksen, and T.H. Stal et al. Dipyridamole augments the antiinflammatory response during human endotoxemia Crit Care 15 2011 R289
32. L. Belardinelli, J.C. Shryock, Y. Song, D. Wang, and M. Srinivas Ionic basis of the electrophysiological actions of adenosine on cardiomyocytes FASEB J 9 1995 359 365
33. A.C. Rankin, R. Brooks, J.N. Ruskin, and B.A. McGovern Adenosine and the treatment of supraventricular tachycardia Am J Med 92 1992 655 664
34. P.Z. Gerczuk, and R.A. Kloner An update on cardioprotection: a review of the latest adjunctive therapies to limit myocardial infarction size in clinical trials J Am Coll Cardiol 59 2012 969 978
35. D.J. Hausenloy, H.E. Bøtker, and G. Condorelli et al. Translating cardioprotection for patient benefit: position paper from the Working Group of Cellular Biology of the Heart of the European Society of Cardiology Cardiovasc Res 98 2013 7 27
36. M. Singh, T. Shah, and K. Khosla et al. Safety and efficacy of intracoronary adenosine administration in patients with acute myocardial infarction undergoing primary percutaneous coronary intervention: a meta-analysis of randomized controlled trials Ther Adv Cardiovasc Dis 6 2012 101 114
37. D. Garcia-Dorado, I. Otaegui, and J.F. Rodriguez Palomares et al. Primary results of the PROMISE trial: myocardial protection with intracoronary adenosine given before reperfusion in patients with STEMI (abstr) Eur Heart J 34 Suppl 1 2013 Available at: http://eurheartj.oxfordjournals.org/content/34/ suppl-1/3736 Accessed February 6, 2014
38. H. Zhang, N.L. Tian, and Z.Y. Hu et al. Three hours continuous injection of adenosine improved left ventricular function and infarct size in patients with ST-segment elevation myocardial infarction Chin Med J (Engl) 125 2012 1713 1719
39. W. Desmet, J. Bogaert, and C. Dubois et al. High-dose intracoronary adenosine for myocardial salvage in patients with acute ST-segment elevation myocardial infarction Eur Heart J 32 2011 867 877
40. J.B. Rose, Z. Naydenova, and A. Bang et al. Equilibrative nucleoside transporter 1 plays an essential role in cardioprotection Am J Physiol Heart Circ Physiol 298 2010 H771 H777
41. Y. Ye, B. Long, J. Qian, J.R. Perez-Polo, and Y. Birnbaum Dipyridamole with low-dose aspirin augments the infarct size-limiting effects of simvastatin Cardiovasc Drugs Ther 24 2010 391 399
42. B.E. Strauer, U.E. Heidland, M.P. Heintzen, and B. Schwartzkopff Pharmacologic myocardial protection during percutaneous transluminal coronary angioplasty by intracoronary application of dipyridamole: impact on hemodynamic function and left ventricular performance J Am Coll Cardiol 28 1996 1119 1126
43. N.K. Burki, and L.Y. Lee Blockade of airway sensory nerves and dyspnea in humans Pulm Pharmacol Ther 23 2010 279 282
44. L. Li, D. Mizel, and Y. Huang et al. Tubuloglomerular feedback and renal function in mice with targeted deletion of the type 1 equilibrative nucleoside transporter Am J Physiol Renal Physiol 304 2013 F382 F389
45. P. Seideman, A. Sollevi, and B.B. Fredholm Additive renal effects of indomethacin and dipyridamole in man Br J Clin Pharmacol 23 1987 323 330
46. A. Wittfeldt, H. Emanuelsson, and G. Brandrup-Wognsen et al. Ticagrelor enhances adenosine-induced coronary vasodilatory responses in humans J Am Coll Cardiol 61 2013 723 727
47. D. Alexopoulos, A. Moulias, and N. Koutsogiannis et al. Differential effect of ticagrelor versus prasugrel on coronary blood flow velocity in patients with non-ST-elevation acute coronary syndrome undergoing percutaneous coronary intervention: an exploratory study Circ Cardiovasc Interv 6 2013 277 283
48. K. Wang, X. Zhou, and Y. Huang et al. Adjunctive treatment with ticagrelor, but not clopidogrel, added to tPA enables sustained coronary artery recanalisation with recovery of myocardium perfusion in a canine coronary thrombosis model Thromb Haemost 104 2010 609 617
49. Y. Birnbaum, S. Ling, M.K. Nanhwan, M. Kodakandla, and Y. Ye Ticagrelor, but not clopidogrel, protects the heart and limits myocardial infarct size (abstr) J Am Coll Cardiol 63 Suppl 2014 1 A22
50. 12 blockers confer direct postconditioning-like protection in reperfused rabbit hearts J Cardiovasc Pharmacol Ther 18 2013 251 262
51. X.M. Yang, Y. Liu, and L. Cui et al. Two classes of anti-platelet drugs reduce anatomical infarct size in monkey hearts Cardiovasc Drugs Ther 27 2013 109 115
52. K. Torngren, J. Ohman, H. Salmi, J. Larsson, and D. Erlinge Ticagrelor improves peripheral arterial function in patients with a previous acute coronary syndrome Cardiology 124 2013 252 258
53. R.F. Storey, S.K. James, and A. Siegbahn et al. Lower mortality following pulmonary adverse events and sepsis with ticagrelor compared to clopidogrel in the PLATO study Platelets 2013 Oct 15 [E-pub ahead of print]
54. I. Biaggioni, J. Onrot, A.S. Hollister, and D. Robertson Cardiovascular effects of adenosine infusion in man and their modulation by dipyridamole Life Sci 39 1986 2229 2236
55. V.L. Serebruany Viewpoint: reversible nature of platelet binding causing transfusion-related acute lung injury (TRALI) syndrome may explain dyspnea after ticagrelor and elinogrel Thromb Haemost 108 2012 1024 1027
56. B.M. Scirica, C.P. Cannon, H. Emanuelsson for the PLATO Investigators The incidence of bradyarrhythmias and clinical bradyarrhythmic events in patients with acute coronary syndromes treated with ticagrelor or clopidogrel in the PLATO (Platelet Inhibition and Patient Outcomes) trial: results of the continuous electrocardiographic assessment substudy J Am Coll Cardiol 57 2011 1908 1916
57. f) by adenosine in rabbit sinoatrial myocytes Circulation 94 1996 734 741
58. R.F. Storey, R.C. Becker, and R.A. Harrington et al. Characterization of dyspnoea in PLATO study patients treated with ticagrelor or clopidogrel and its association with clinical outcomes Eur Heart J 32 2011 2945 2953
59. R.F. Storey, K.P. Bliden, and S.B. Patil et al. Incidence of dyspnea and assessment of cardiac and pulmonary function in patients with stable coronary artery disease receiving ticagrelor, clopidogrel, or placebo in the ONSET/OFFSET study J Am Coll Cardiol 56 2010 185 193
60. V. Serebruany, I. Pokov, W. Kuliczkowski, J. Vahabi, and D. Atar Incidence and causes of new-onset dyspnea in 3,719 patients treated with clopidogrel and aspirin combination after coronary stenting Thromb Haemost 100 2008 314 318